Lee Dasom, Goyal Anmol, Wang William L, Ananth Snegha, Lau Eric, Binkley Michael S, Bharadwaj Sushma, Dahiya Saurabh
Division of Hematology Stanford University School of Medicine Stanford California USA.
Division of Blood and Marrow Transplantation and Cellular Therapy Stanford University School of Medicine Stanford California USA.
EJHaem. 2024 Feb 12;5(1):153-156. doi: 10.1002/jha2.859. eCollection 2024 Feb.
The safety and efficacy of CAR T-cell therapy are unknown in pediatric and adolescent patients with relapsed or refractory primary mediastinal large B-cell lymphoma (R/R PMBCL) which is associated with dismal prognosis. Here, we present a case report of a 16-year-old patient with R/R PMBCL treated with lisocabtagene maraleucel including correlative studies. Patient achieved complete response at 6 months without cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome. She only experienced mild cytopenias, requiring filgrastim once. This report highlights the safety and efficacy of lisocabtagene maraleucel in this population, warranting prospective studies to improve clinical outcomes.
对于复发或难治性原发性纵隔大B细胞淋巴瘤（R/R PMBCL）的儿科和青少年患者，嵌合抗原受体（CAR）T细胞疗法的安全性和有效性尚不清楚，该疾病预后不佳。在此，我们报告一例16岁R/R PMBCL患者接受利妥昔单抗治疗的病例报告，包括相关研究。患者在6个月时达到完全缓解，未出现细胞因子释放综合征和免疫效应细胞相关神经毒性综合征。她仅经历了轻度血细胞减少，仅需一次使用非格司亭。本报告强调了利妥昔单抗在该人群中的安全性和有效性，有必要进行前瞻性研究以改善临床结局。
